ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (Nasdaq: HGSI) will host a conference call at 8:15 AM Eastern this morning to discuss the positive opinion received from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for BENLYSTA® (belimumab). A separate press release announcing the CHMP positive opinion was distributed just moments ago.
Investors may listen to the call by dialing 888-455-2265 or 719-457-2601, passcode 9676021, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 9676021.
Today’s conference call also will be webcast and can be accessed at www.hgsi.com. It is recommended that investors interested in listening to the live webcast log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.
About Human Genome Sciences
Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.
For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to [email protected] or by calling HGS at (877) 822-8472.
HGS, Human Genome Sciences, and BENLYSTA are trademarks of Human Genome Sciences, Inc.
Human Genome Sciences, Inc.
Director, Corporate Public Relations
Vice President, Corporate Communications
Claudine Prowse, Ph.D.
Executive Director, Investor Relations
Senior Director, Investor Relations
KEYWORDS: United States Europe North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical